الأصول تغيير تاريخ
AbbVie USD 133.96B 62M 2025-12
Agenus USD 226.8M 7.09M 2025-12
Amgen USD 92.5B 1.92B 2026-03
AstraZeneca USD 114.02B 59M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Celldex Therapeutics USD 582.98M 65.46M 2025-12
CSL USD 37.9B 1.5B 2025-12
Eli Lilly USD 116.58B 4.1B 2026-03
Gilead Sciences USD 59.02B 490M 2025-12
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
Glaxosmithkline GBP 82.34B 102.25M 2025-12
Incyte USD 7.34B 381.14M 2026-03
Intrexon USD 73.16M 77.88M 2024-06
J&J USD 200.89B 1.68B 2026-03
Jiangsu Hengrui CNY 71.29B 1.43B 2026-03
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
MacroGenics USD 256.85M 13.92M 2025-12
Merck EUR 51.53B 600M 2025-12
Merck USD 128.68B 8.18B 2026-03
Northwest Biotherapeutics USD 30.61M 1.06M 2025-09
Novartis USD 118.53B 7.58B 2026-03
Novavax USD 1.18B 3.38M 2025-12
Pfizer USD 207.62B 542M 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Veracyte USD 1.41B 38.23M 2025-12